Nurix and Roche closed their global bexobrutideg collaboration after the Hart-Scott-Rodino waiting period expired. Closing converts a previously announced agreement into an operative partnership and triggers a $700 million upfront payment, with up to…
Roche’s discontinuation of tominersen in Huntington’s disease creates an important platform-level readthrough for Wave Life Sciences and its allele-selective antisense oligonucleotide candidate, WVE-003.The key distinction is biological selectivity. Tominersen was designed to lower total…
Nurix and Roche announced a global collaboration for bexobrutideg, a potential best-in-class BTK degrader across hematology and immunology.
